Helix BioPharma Corp. (TSX: HBP, OTC PINK: HBPCF, FRANKFURT: HBP0), a clinical-stage oncology company, has announced the appointment of Markus Loeffler, MD, MBA, as its new Chief Medical Officer. This strategic hire comes at a pivotal time as the company prepares to enter a more execution-focused phase of clinical development, with multiple programs approaching critical regulatory and clinical milestones.
Dr. Loeffler brings over three decades of leadership in oncology drug development, with extensive experience advancing therapeutics from early clinical stages through to regulatory approval. His career includes senior roles at Roche, Advanced Accelerator Applications, Mundipharma, NH TherAguix, Corbus Pharmaceuticals, and SK Life Science. Notably, he led the pivotal Phase III program for Lutathera® (lutetium Lu 177 dotatate), which received approval for the treatment of certain gastroenteropancreatic neuroendocrine tumors. This breadth of experience is expected to be instrumental as Helix advances its pipeline.
In his new role, Dr. Loeffler will oversee the strategy and execution of Helix's clinical programs, including the planned Phase Ib/II evaluation of L-DOS47 in combination with pembrolizumab for first-line non-small cell lung cancer (NSCLC). He will also guide LEUMUNA™, a pre-IND oral immune checkpoint modulator, toward clinical development for leukemia relapse following allogeneic stem cell transplantation.
Thomas Mehrling, MD, PhD, Chief Executive Officer of Helix, expressed confidence in the appointment, stating, "I've had the privilege of working with Markus before, and I have seen firsthand his ability to translate innovative science into well-executed clinical development programs. He is an outstanding clinical development leader with a strong track record of advancing innovative oncology therapies through the development pathway. His expertise will be instrumental as we advance L-DOS47 into its next stage of clinical development and prepare LEUMUNA to enter the clinic."
Dr. Loeffler echoed this sentiment, saying, "I'm excited to join Helix at such an important stage in its evolution. The Company's pipeline combines strong scientific foundations with clear clinical development opportunities. I am particularly enthused by the opportunity to advance L-DOS47 in combination with checkpoint inhibition and to bring LEUMUNA toward its first clinical evaluation. I look forward to working alongside the team to translate these programs into meaningful new treatment options for patients with difficult-to-treat cancers."
The appointment of Dr. Loeffler signals Helix's commitment to advancing its oncology pipeline, which also includes GEMCEDA™, a pre-IND gemcitabine prodrug for advanced solid tumors. With a focus on difficult-to-treat cancers, the company is positioning itself for significant progress under this new leadership. For more information about Helix BioPharma and its pipeline, visit https://www.helixbiopharma.com/.
